Latest


Natco Pharma gets USFDA approval for leukemia drug

  •   Fri, Jan 06 2017 03:09:51 PM

Mumbai, Jan 6 (IANS): Natco Pharma on Friday said it has received the USFDA approval to manufacture a drug for injections used in the treatement of chronic lymphocytic leukemia (CLL) and non-Hodgkins lymphoma.

"We are pleased to announce the final approval of Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (USFDA) for generic version of Bendamustine Hydrochloride powder for injection," Natco Pharma said in a BSE filing here.

Natco plans to launch this drug on November 1, 2019, or earlier, through its marketing partner Breckenridge Pharmaceutical Inc, in the US market, it said. 

Currently, US-based Cephalon Inc sells Bendamustine Hydrochloride powder for injection under the brand name Treanda, which is indicated for the treatment of patients with CLL and non-Hodgkin's lymphoma. 

Treanda had US sales of approximately $133 million for 12 months ending November 2016, according to IMS Health. 
  

Top Stories


Leave a Comment

Title: Natco Pharma gets USFDA approval for leukemia drug



You have 2000 characters left.

Disclaimer:

Please write your correct name and email address. Kindly do not post any personal, abusive, defamatory, infringing, obscene, indecent, discriminatory or unlawful or similar comments. Daijiworld.com will not be responsible for any defamatory message posted under this article.

Please note that sending false messages to insult, defame, intimidate, mislead or deceive people or to intentionally cause public disorder is punishable under law. It is obligatory on Daijiworld to provide the IP address and other details of senders of such comments, to the authority concerned upon request.

Hence, sending offensive comments using daijiworld will be purely at your own risk, and in no way will Daijiworld.com be held responsible.

You might also like